Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A Three-Point message could boost medication adherence in chronic disease

NCT ID NCT06748118

Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests whether a simple, standardized, and repeated message from healthcare professionals can improve how well patients with chronic diseases follow their treatment plans. About 1,200 adults with chronic conditions will receive this message during regular consultations. The goal is to see if this approach increases the percentage of patients who take their medications as prescribed.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
simple, standardized, redundant 3-point message delivered by healthcare professionals
What this could lead to
If it works, this approach could offer a low-cost way to help many patients with chronic conditions take their medications as prescribed, improving health outcomes.
What could go wrong
The message is simple and may not be enough to change long-term habits. Results depend on how consistently healthcare professionals deliver it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,210 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients (age ≥ 18 years) * Affiliated to the French social security system * Followed in hospital for a chronic pathology within a formalized care pathway * Having signed a consent form to participate in the study. Exclusion Criteria: * Patients included in the control period. * Patients under guardianship. * Pregnant or breast-feeding patients. * Patients taking part in research on compliance

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

allergic disease Chronic Disease Treatment Adherence and Compliance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic disease Delivery simple, standardized & redundant message to patient Therapeutic adherence Training group, sensitivity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH d'Antibes

    RECRUITING

    Antibes, France, 06606, France

  • CHU d'Angers

    RECRUITING

    Angers, France, 49933, France

  • CHU de Nantes

    RECRUITING

    Nantes, France, 44000, France

  • CHU de Toulouse

    RECRUITING

    Toulouse, France, 31059, France

  • CHU de Tours

    RECRUITING

    Tours, France, 37000, France

  • Hôpital Bicêtre

    RECRUITING

    Paris, France, 94270, France

  • Hôpital Corentin Celton

    RECRUITING

    Issy-les-Moulineaux, France, 92133, France

  • Hôpital La Timone

    RECRUITING

    Marseille, France, 13005, France

  • Hôpital de la Conception

    RECRUITING

    Marseille, France, 13005, France

  • Hôpital européen Georges-Pompidou

    RECRUITING

    Paris, France, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.